Cargando…

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

BACKGROUND: Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients. MAIN BODY: A total number of 539 patients were enrolled in f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabiee Rad, Mehrdad, Ghasempour Dabaghi, Ghazal, Habibi, Danial
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837360/ https://www.ncbi.nlm.nih.gov/pubmed/36633717 http://dx.doi.org/10.1186/s43044-023-00328-7

Ejemplares similares

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
por: Memon, Areeba, et al.
Publicado: (2023)

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023)

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023)

Obstructed Descending Colon Mass Presented With Bochdalek Hernia: A Case Report
por: Eslamian, Mohammad, et al.
Publicado: (2023)

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022)

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten
por: Mathai, Susan, et al.
Publicado: (2022)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis
por: Rangwala, Hussain Sohail, et al.
Publicado: (2023)

Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial
por: Tian, Zhuang, et al.
Publicado: (2023)

The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
por: DeVries, J Hans, et al.
Publicado: (2023)

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy
por: Taddei-Allen, Patty
Publicado: (2022)

A transvaginal ultrasound-based diagnostic calculator for uterus post-cesarean scar defect
por: Allameh, Zahra, et al.
Publicado: (2023)

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)
por: Langley, Paul C
Publicado: (2022)

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment
por: Wang, Kai, et al.
Publicado: (2023)

Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca(2+) flux caused by thin filament hypertrophic cardiomyopathy mutations
por: Sparrow, Alexander J., et al.
Publicado: (2020)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

Mavacamten: First Approval
por: Keam, Susan J.
Publicado: (2022)

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy
por: Tian, Zhuang, et al.
Publicado: (2023)

Correction to: Mavacamten: First Approval
por: Keam, Susan J.
Publicado: (2022)

Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: A systematic review and meta‐analysis
por: Yang, Haonan, et al.
Publicado: (2020)

Comparing the efficacy and safety of medications in adults with hypertrophic cardiomyopathy: a systematic review and network meta-analysis
por: Mi, Keying, et al.
Publicado: (2023)

Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy
por: Chen, Chris, et al.
Publicado: (2023)

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

Safety Monitoring for Obstructive Hypertrophic Cardiomyopathy During Exercise
por: Nakayama, Atsuko, et al.
Publicado: (2020)

Metalloproteinases and Hypertrophic Cardiomyopathy: A Systematic Review
por: Serraino, Giuseppe Filiberto, et al.
Publicado: (2023)

Current therapies for hypertrophic cardiomyopathy: a systematic review and meta‐analysis of the literature
por: Bayonas‐Ruiz, Adrián, et al.
Publicado: (2022)

Myosin in autoinhibited off state(s), stabilized by mavacamten, can be recruited via inotropic effectors
por: Ma, Weikang, et al.
Publicado: (2023)

The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy
por: Kittleson, Mark D, et al.
Publicado: (2021)

Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial
por: Wheeler, Matthew T., et al.
Publicado: (2023)

Hypertrophic Obstructive Cardiomyopathy
por: Cohen, Lawrence S.
Publicado: (1972)

The genetics of hypertrophic cardiomyopathy
por: Akhtar, Mohammed, et al.
Publicado: (2018)

Disopyramide for Hypertrophic Cardiomyopathy
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2019)

Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients
por: Adler, Arnon, et al.
Publicado: (2017)

Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis
por: Bayonas-Ruiz, Adrián, et al.
Publicado: (2021)

Is There a Sex Difference in the Prognosis of Hypertrophic Cardiomyopathy? A Systematic Review and Meta‐Analysis
por: Zhao, Huilei, et al.
Publicado: (2023)

Efficacy and safety of alcohol septal ablation in patients over 65 years old with obstructive hypertrophic cardiomyopathy
por: Cheddadi, Laila, et al.
Publicado: (2017)

Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy
por: Meng, Yanhai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ok603tehca267s1324cp3uctde